Hemeema Limited 31/05/2020 iXBRL

Hemeema Limited 31/05/2020 iXBRL

HEMEEMA LIMITED - Company Information

Print Friendly Version

31/05/2020 2020-05-31 false false false false false false false false false false true false false true false false false false false false false false No description of principal activities is disclosed 2019-06-01 Sage Accounts Production 20.0 - FRS102_2014 xbrli:pure xbrli:shares iso4217:GBP 02583240 2019-06-01 2020-05-31 02583240 2020-05-31 02583240 2019-05-31 02583240 2018-06-01 2019-05-31 02583240 2019-05-31 02583240 core:FurnitureFittingsToolsEquipment 2019-06-01 2020-05-31 02583240 core:MotorVehicles 2019-06-01 2020-05-31 02583240 core:OnerousContractsExcludingVacantProperties 2019-06-01 2020-05-31 02583240 core:NetGoodwill 2019-06-01 2020-05-31 02583240 bus:RegisteredOffice 2019-06-01 2020-05-31 02583240 bus:LeadAgentIfApplicable 2019-06-01 2020-05-31 02583240 bus:Director1 2019-06-01 2020-05-31 02583240 bus:Director2 2019-06-01 2020-05-31 02583240 bus:CompanySecretary1 2019-06-01 2020-05-31 02583240 core:WithinOneYear 2020-05-31 02583240 core:WithinOneYear 2019-05-31 02583240 core:AfterOneYear 2020-05-31 02583240 core:UKTax 2019-06-01 2020-05-31 02583240 core:UKTax 2018-06-01 2019-05-31 02583240 core:ShareCapital 2020-05-31 02583240 core:ShareCapital 2019-05-31 02583240 core:RetainedEarningsAccumulatedLosses 2020-05-31 02583240 core:RetainedEarningsAccumulatedLosses 2019-05-31 02583240 core:CostValuation core:Non-currentFinancialInstruments 2019-05-31 02583240 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2020-05-31 02583240 core:CostValuation core:Non-currentFinancialInstruments 2020-05-31 02583240 core:Non-currentFinancialInstruments 2020-05-31 02583240 core:Non-currentFinancialInstruments 2019-05-31 02583240 bus:SmallEntities 2019-06-01 2020-05-31 02583240 bus:AuditExemptWithAccountantsReport 2019-06-01 2020-05-31 02583240 bus:AbridgedAccounts 2019-06-01 2020-05-31 02583240 bus:SmallCompaniesRegimeForAccounts 2019-06-01 2020-05-31 02583240 bus:PrivateLimitedCompanyLtd 2019-06-01 2020-05-31 02583240 core:ComputerEquipment 2019-06-01 2020-05-31
Statement of consent to prepare abridged financial statements
All of the members of Hemeema Limited have consented to the preparation of the abridged statement of comprehensive income and the abridged statement of financial position for the current year ending 31 May 2020 in accordance with Section 444(2A) of the Companies Act 2006.
Company registration number: 02583240
Hemeema Limited
Unaudited filleted abridged financial statements
31 May 2020
Hemeema Limited
Contents
Directors and other information
Accountants report
Abridged statement of financial position
Notes to the financial statements
Hemeema Limited
Directors and other information
Directors Mr Pareshkumar Bhanji Modasia
Mrs Kishoree Paresh Modasia
Secretary Mrs Kishoree Paresh Modasia
Company number 02583240
Registered office 47 Home Park Road
Wimbledon Park
London
SW19 7HS
Accountants Doshi & Co. Accountants
6th Floor AMP House
Dingwall Road
Croydon
CR0 2LX
Hemeema Limited
Report to the board of directors on the preparation of the
unaudited statutory financial statements of Hemeema Limited
Year ended 31 May 2020
As described on the statement of financial position, the directors of the company are responsible for the preparation of the financial statements for the year ended 31 May 2020 which comprise the abridged statement of financial position and related notes.
You consider that the company is exempt from an audit under the Companies Act 2006. In accordance with your instructions we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to us.
Doshi & Co. Accountants
6th Floor AMP House
Dingwall Road
Croydon
CR0 2LX
26 May 2021
Hemeema Limited
Abridged statement of financial position
31 May 2020
2020 2019
Note £ £ £ £
Fixed assets
Intangible assets 6 1 1
Tangible assets 7 14,224 18,966
Investments 8 211,464 141,464
_______ _______
225,689 160,431
Current assets
Stocks 72,250 70,000
Debtors:
Amounts falling due within one year 2,446,783 2,394,425
Cash at bank and in hand 190,197 169,217
_______ _______
2,709,230 2,633,642
Creditors: amounts falling due
within one year ( 197,465) ( 267,706)
_______ _______
Net current assets 2,511,765 2,365,936
_______ _______
Total assets less current liabilities 2,737,454 2,526,367
Creditors: amounts falling due
after more than one year ( 50,000) -
Provisions for liabilities ( 944) 1,685
_______ _______
Net assets 2,686,510 2,528,052
_______ _______
Capital and reserves
Called up share capital 553 553
Profit and loss account 2,685,957 2,527,499
_______ _______
Shareholders funds 2,686,510 2,528,052
_______ _______
For the year ending 31 May 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 26 May 2021 , and are signed on behalf of the board by:
Mr Pareshkumar Bhanji Modasia
Director
Company registration number: 02583240
Hemeema Limited
Notes to the financial statements
Year ended 31 May 2020
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Hemeema Limited, 47 Home Park Road, Wimbledon Park, London, SW19 7HS.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Operating leases
Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Goodwill
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Fittings fixtures and equipment - 25 % reducing balance
Motor vehicles - 25 % reducing balance
User defined asset - 25 % reducing balance
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Fixed asset investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 12 (2019: 10 ).
5. Tax on profit
Major components of tax expense
2020 2019
£ £
Current tax:
UK current tax expense 59,456 59,463
_______ _______
Deferred tax:
Origination and reversal of timing differences 2,629 ( 1,818)
_______ _______
Tax on profit 62,085 57,645
_______ _______
6. Intangible assets
£
Cost
At 1 June 2019 and 31 May 2020 361,900
_______ |
Amortisation
At 1 June 2019 and 31 May 2020 361,899
_______ |
Carrying amount
At 31 May 2020 1
_______ |
At 31 May 2019 1
_______ |
7. Tangible assets
£
Cost
At 1 June 2019 and 31 May 2020 148,082
_______
Depreciation
At 1 June 2019 129,116
Charge for the year 4,742
_______
At 31 May 2020 133,858
_______
Carrying amount
At 31 May 2020 14,224
_______
At 31 May 2019 18,966
_______
8. Investments
£
Cost
At 1 June 2019 141,464
Additions 70,000
_______
At 31 May 2020 211,464
_______
Impairment
At 1 June 2019 and 31 May 2020 -
_______
Carrying amount
At 31 May 2020 211,464
_______
At 31 May 2019 141,464
_______
9. Events after the end of the reporting period
After the balance sheet date, we have seen macro-economic uncertainty with regard to the general trading conditions as a result of COVID-19 (Coronavirus) outbreak leading to disruption to business activity. The directors consider the emergence and spread of COVID-19 to be non-adjusting post-balance sheet event . Given the inherent uncertainties, it is not practicable at this time to determine the impact of COVID-19 on the company or provide a quantitative estimate of this impact. We confirm that no other event has occurred between the Balance Sheet date and the date of approval of these accounts, which will materially affect the amounts or manner in which significant items are reflected in the accounts.
10. Controlling party
The directors control the company by virtue of their shareholdings in the company.